Gosebruch Henry O's Form 4 filing
AbbVie Inc. (ABBV) · filed Mar 2, 2022
- Accession no.
- 0001179110-22-001923
- Filed
- Mar 2, 2022
- Trade date
- Mar 1, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $3.68M. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001179110-22-003107 (May 20, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gosebruch Henry OCIK 0001659625 | Officer (EVP, Chief Strategy Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock, $0.01 par value | SSaleDisposed | −15,733 | $146.81F1 | −$2,309,761.73 | 25,890 | Direct | |
| Mar 1, 2022 | Common Stock, $0.01 par value | SSaleDisposed | −5,167 | $147.60F2 | −$762,649.2 | 20,723 | Direct | |
| Mar 1, 2022 | Common Stock, $0.01 par value | SSaleDisposed | −4,000 | $148.71F3 | −$594,840 | 16,723 | Direct | |
| Mar 1, 2022 | Common Stock, $0.01 par value | SSaleDisposed | −100 | $149.38F4 | −$14,938 | 16,623 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).